(PFE) Pfizer - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US7170811035
Medicines, Vaccines, Biosimilars, Injectables, Anti-Infectives
Dividends
| Dividend Yield | 6.69% |
| Yield on Cost 5y | 5.32% |
| Yield CAGR 5y | 2.53% |
| Payout Consistency | 94.0% |
| Payout Ratio | 58.7% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 24.9% |
| Value at Risk 5%th | 38.8% |
| Relative Tail Risk | -5.25% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.26 |
| Alpha | -2.15 |
| CAGR/Max DD | -0.29 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.448 |
| Beta | 0.444 |
| Beta Downside | 0.602 |
| Drawdowns 3y | |
|---|---|
| Max DD | 55.31% |
| Mean DD | 40.15% |
| Median DD | 44.42% |
Description: PFE Pfizer December 02, 2025
Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures, markets and distributes a broad portfolio of medicines and vaccines across therapeutic areas such as cardiovascular, migraine, infectious disease, oncology, immunology and rare diseases. Its flagship brands include Eliquis, Prevnar, Comirnaty, Paxlovid and a growing line of biosimilars and specialty drugs, and the firm also operates a contract-manufacturing business serving hospitals, pharmacies and government agencies worldwide.
Key recent metrics: FY 2023 revenue reached $100.3 billion, up ≈ 3 % YoY, while diluted EPS was $3.73 and the company paid a dividend yielding roughly 4.1 %. R&D spending remained high at about $13 billion, reflecting continued investment in mRNA platforms, oncology pipelines (e.g., Ibrance, Tivdak) and biosimilar expansion. The sector’s growth is driven by an aging population, rising chronic-disease prevalence and sustained U.S. healthcare expenditure, but pricing pressure and patent cliffs remain material headwinds.
For a deeper, data-driven valuation framework, you may find ValueRay’s analyst tools worth a look.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (9.82b TTM) > 0 and > 6% of Revenue (6% = 3.77b TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA 1.22pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 16.45% (prev 0.02%; Δ 16.43pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 13.08b > Net Income 9.82b (YES >=105%, WARN >=100%) |
| Net Debt (60.37b) to EBITDA (21.17b) ratio: 2.85 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.28 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (5.71b) change vs 12m ago 0.16% (target <= -2.0% for YES) |
| Gross Margin 71.19% (prev 58.73%; Δ 12.46pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 29.32% (prev 27.54%; Δ 1.79pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.36 (EBITDA TTM 21.17b / Interest Expense TTM 2.70b) >= 6 (WARN >= 3) |
Altman Z'' 3.70
| (A) 0.05 = (Total Current Assets 46.92b - Total Current Liabilities 36.60b) / Total Assets 208.73b |
| (B) 0.58 = Retained Earnings (Balance) 121.15b / Total Assets 208.73b |
| (C) 0.07 = EBIT TTM 14.47b / Avg Total Assets 214.10b |
| (D) 0.98 = Book Value of Equity 113.56b / Total Liabilities 115.64b |
| Total Rating: 3.70 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 57.54
| 1. Piotroski 6.0pt |
| 2. FCF Yield 5.38% |
| 3. FCF Margin 16.53% |
| 4. Debt/Equity 0.66 |
| 5. Debt/Ebitda 2.85 |
| 6. ROIC - WACC (= 4.45)% |
| 7. RoE 10.91% |
| 8. Rev. Trend -68.94% |
| 9. EPS Trend -46.23% |
What is the price of PFE shares?
As of December 05, 2025, the stock is trading at USD 25.70 with a total of 33,537,685 shares traded.
Over the past week, the price has changed by -0.16%, over one month by +7.62%, over three months by +6.57% and over the past year by +9.23%.
Over the past week, the price has changed by -0.16%, over one month by +7.62%, over three months by +6.57% and over the past year by +9.23%.
Is PFE a buy, sell or hold?
Pfizer has received a consensus analysts rating of 3.56.
Therefor, it is recommend to hold PFE.
- Strong Buy: 7
- Buy: 2
- Hold: 15
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the PFE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 29 | 13% |
| Analysts Target Price | 29 | 13% |
| ValueRay Target Price | 26.4 | 2.9% |
PFE Fundamental Data Overview November 29, 2025
Market Cap USD = 146.18b (146.18b USD * 1.0 USD.USD)
P/E Trailing = 14.9477
P/E Forward = 8.4818
P/S = 2.3283
P/B = 1.5752
P/EG = 14.1419
Beta = 0.425
Revenue TTM = 62.78b USD
EBIT TTM = 14.47b USD
EBITDA TTM = 21.17b USD
Long Term Debt = 56.55b USD (from longTermDebt, last quarter)
Short Term Debt = 4.30b USD (from shortTermDebt, last quarter)
Debt = 61.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 60.37b USD (from netDebt column, last quarter)
Enterprise Value = 192.91b USD (146.18b + Debt 61.71b - CCE 14.98b)
Interest Coverage Ratio = 5.36 (Ebit TTM 14.47b / Interest Expense TTM 2.70b)
FCF Yield = 5.38% (FCF TTM 10.38b / Enterprise Value 192.91b)
FCF Margin = 16.53% (FCF TTM 10.38b / Revenue TTM 62.78b)
Net Margin = 15.64% (Net Income TTM 9.82b / Revenue TTM 62.78b)
Gross Margin = 71.19% ((Revenue TTM 62.78b - Cost of Revenue TTM 18.09b) / Revenue TTM)
Gross Margin QoQ = 74.95% (prev 64.29%)
Tobins Q-Ratio = 0.92 (Enterprise Value 192.91b / Total Assets 208.73b)
Interest Expense / Debt = 1.06% (Interest Expense 652.0m / Debt 61.71b)
Taxrate = -6.48% (negative due to tax credits) (-216.0m / 3.33b)
NOPAT = 15.41b (EBIT 14.47b * (1 - -6.48%)) [negative tax rate / tax credits]
Current Ratio = 1.28 (Total Current Assets 46.92b / Total Current Liabilities 36.60b)
Debt / Equity = 0.66 (Debt 61.71b / totalStockholderEquity, last quarter 92.80b)
Debt / EBITDA = 2.85 (Net Debt 60.37b / EBITDA 21.17b)
Debt / FCF = 5.82 (Net Debt 60.37b / FCF TTM 10.38b)
Total Stockholder Equity = 90.01b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.71% (Net Income 9.82b / Total Assets 208.73b)
RoE = 10.91% (Net Income TTM 9.82b / Total Stockholder Equity 90.01b)
RoCE = 9.88% (EBIT 14.47b / Capital Employed (Equity 90.01b + L.T.Debt 56.55b))
RoIC = 10.16% (NOPAT 15.41b / Invested Capital 151.69b)
WACC = 5.71% (E(146.18b)/V(207.89b) * Re(7.65%) + D(61.71b)/V(207.89b) * Rd(1.06%) * (1-Tc(-0.06)))
Discount Rate = 7.65% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 0.59%
[DCF Debug] Terminal Value 74.43% ; FCFE base≈9.52b ; Y1≈7.55b ; Y5≈5.05b
Fair Price DCF = 16.53 (DCF Value 93.99b / Shares Outstanding 5.69b; 5y FCF grow -24.64% → 3.0% )
EPS Correlation: -46.23 | EPS CAGR: -5.60% | SUE: 2.26 | # QB: 9
Revenue Correlation: -68.94 | Revenue CAGR: -9.12% | SUE: 0.08 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.77 | Chg30d=+0.013 | Revisions Net=+4 | Analysts=7
EPS next Year (2026-12-31): EPS=3.10 | Chg30d=-0.073 | Revisions Net=-9 | Growth EPS=-1.2% | Growth Revenue=-1.1%
P/E Trailing = 14.9477
P/E Forward = 8.4818
P/S = 2.3283
P/B = 1.5752
P/EG = 14.1419
Beta = 0.425
Revenue TTM = 62.78b USD
EBIT TTM = 14.47b USD
EBITDA TTM = 21.17b USD
Long Term Debt = 56.55b USD (from longTermDebt, last quarter)
Short Term Debt = 4.30b USD (from shortTermDebt, last quarter)
Debt = 61.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 60.37b USD (from netDebt column, last quarter)
Enterprise Value = 192.91b USD (146.18b + Debt 61.71b - CCE 14.98b)
Interest Coverage Ratio = 5.36 (Ebit TTM 14.47b / Interest Expense TTM 2.70b)
FCF Yield = 5.38% (FCF TTM 10.38b / Enterprise Value 192.91b)
FCF Margin = 16.53% (FCF TTM 10.38b / Revenue TTM 62.78b)
Net Margin = 15.64% (Net Income TTM 9.82b / Revenue TTM 62.78b)
Gross Margin = 71.19% ((Revenue TTM 62.78b - Cost of Revenue TTM 18.09b) / Revenue TTM)
Gross Margin QoQ = 74.95% (prev 64.29%)
Tobins Q-Ratio = 0.92 (Enterprise Value 192.91b / Total Assets 208.73b)
Interest Expense / Debt = 1.06% (Interest Expense 652.0m / Debt 61.71b)
Taxrate = -6.48% (negative due to tax credits) (-216.0m / 3.33b)
NOPAT = 15.41b (EBIT 14.47b * (1 - -6.48%)) [negative tax rate / tax credits]
Current Ratio = 1.28 (Total Current Assets 46.92b / Total Current Liabilities 36.60b)
Debt / Equity = 0.66 (Debt 61.71b / totalStockholderEquity, last quarter 92.80b)
Debt / EBITDA = 2.85 (Net Debt 60.37b / EBITDA 21.17b)
Debt / FCF = 5.82 (Net Debt 60.37b / FCF TTM 10.38b)
Total Stockholder Equity = 90.01b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.71% (Net Income 9.82b / Total Assets 208.73b)
RoE = 10.91% (Net Income TTM 9.82b / Total Stockholder Equity 90.01b)
RoCE = 9.88% (EBIT 14.47b / Capital Employed (Equity 90.01b + L.T.Debt 56.55b))
RoIC = 10.16% (NOPAT 15.41b / Invested Capital 151.69b)
WACC = 5.71% (E(146.18b)/V(207.89b) * Re(7.65%) + D(61.71b)/V(207.89b) * Rd(1.06%) * (1-Tc(-0.06)))
Discount Rate = 7.65% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 0.59%
[DCF Debug] Terminal Value 74.43% ; FCFE base≈9.52b ; Y1≈7.55b ; Y5≈5.05b
Fair Price DCF = 16.53 (DCF Value 93.99b / Shares Outstanding 5.69b; 5y FCF grow -24.64% → 3.0% )
EPS Correlation: -46.23 | EPS CAGR: -5.60% | SUE: 2.26 | # QB: 9
Revenue Correlation: -68.94 | Revenue CAGR: -9.12% | SUE: 0.08 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.77 | Chg30d=+0.013 | Revisions Net=+4 | Analysts=7
EPS next Year (2026-12-31): EPS=3.10 | Chg30d=-0.073 | Revisions Net=-9 | Growth EPS=-1.2% | Growth Revenue=-1.1%
Additional Sources for PFE Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle